All News

Aurelie Najm Tweet
#ACR23 #ACRpearls Breaking news: Pizza 🍕 DOES improve disease activity in RA Eating half a pizza > 1 time a week reduces SDAI -3.6 Dr Philip Seo warns us though, authors emphasizes it only applies to the ‘REAL’ Italian pizza👌🏻 #yearinreview @RheumNow https://t.co/xt7uEYFoW1
TheDaoIndex Tweet
KDAO2011
Checkpoint inhibitor assc arthritis may be assc with a particular clonal T cell that produce type I IFN. #YearInReview #ACR23 @RheumNow https://t.co/CEB0lCkzls
Dr. Rachel Tate Tweet
Dr. Seo sells the benefits of pizza consumption in RA at #ACR23 YiR. This Italian study followed adult RA pts who ate half a pizza (Italian sized!) > 1 x/week self reported improvement in their disease! Personally, I can assure that mozzarella and olive oil significantly improve… https://t.co/zLocmDu4Z4 https://t.co/WkCZHteL8O
TheDaoIndex Tweet
KDAO2011
Maintenance regimen for #AAV- AZP and On demand RTX inferior to RTX q6 months. Scheduled RTX for 18 or 36 months is better and results the same. AES similar in all group #ACR23 @RheumNow #YearinReview https://t.co/SpA9mY6syZ
Mike Putman Tweet
EBRheum
Slides (vexingly) unavailable for ILD guideline talk, thanks @DrPujaMehta1 for the quick snap! As expected, ILD guidelines "suggestion" for who to screen is "way way more than before" My thoughts in full: https://t.co/QC7ZLxjdJk @RheumNow #ACR23 https://t.co/BuhJFgpfZh
Robert B Chao, MD Tweet
What are you using for ANCA vasculitis maintenance? Not much difference in AZA vs. RTX on demand 70% relapse free in RTX q6 month for 18 months NO difference in similar 36 month group Should maintenance w/ RTX only last for 18 months? Food for thought @RheumNow #ACRbest https://t.co/zNdIEODpeS
Robert B Chao, MD Tweet
Very cool targeted T cell ab treatment against TRBV9+ T cells provided remission in ankylosing spondylitis! Albeit only case report However Phase 2 ongoing @RheumNow #ACR23 https://t.co/pm64QeTo1U
Mike Putman Tweet
EBRheum
Brilliant summary slide re:RA and PsA during an as-always entertaiing by Dr. Seo Personal opinion? -Persolimab will have narrow role & may cause CA -BIME will be 2nd line for PsA -Tyk-2's will be the next big thing Also... time for H2H trials!!! @RheumNow #ACR23 https://t.co/lDvsK8h7WH
Dr. Rachel Tate Tweet
#ACR23 YiR! Dr. P. Seo reviews 2023 novel therapeutic agents we may see on the horizon. @RheumNow https://t.co/d0V41jAh3G
sheila Tweet
Considering a career in Rheumatology? Dr. Philip Seo shares latest data from Lancet Rheumatology on the burden of disease of MSK disorders 👉123%⬆️since 1990 👉⬆️by 50% in 2050! Year in Review #ACR23 @RheumNow @rheumarhyme @doktora_ging @PhRheumaJr https://t.co/iypUn9MTu6
Robert B Chao, MD Tweet
NORD-STAR study RA pts treated with MTX + certolizumab, abatacept, tocilizumab or triple therapy Certolizumab and Abatacept share 1st place! Toci 2nd Should we place abatacept higher on the RA tx hierarchy? @RheumNow #ACR23 https://t.co/QvyzkLOcmX
Mike Putman Tweet
EBRheum
Still disgesting NORD-STAR, kind of surprised by the TCZ response? As per usual, ABA is probably an under-used option for RA @RheumNow #ACR23 https://t.co/QKyeuhqnXB
Md Yuzaiful Md Yusof Tweet
#ACR23 I’ll be at the Poster Hall tomorrow 12/11/23 between 9-11 am to present our work on clinical and biomarkers to exclude imminent autoimmune connective tissue disease #lupus #sjogren in people with ANA+. Do come and say hi 👋🏼 😃 https://t.co/wzRB7QXZsF
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×